Clinical Trials Browser

Recruiting × MSI-H/dMMR Solid Tumors × Other solid neoplasm × Clear all

NCT03736889 2025-12-17

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

MSI-H/dMMR Solid Tumors